How can we get someone with an understanding of microbiology/chemistry to help us figure out if this is the correct patent or not?
Sm04554
Collapse
X
-
How can we get someone with an understanding of microbiology/chemistry to help us figure out if this is the correct patent or not?
http://www.google.com/patents/US20140080902Comment
-
Comment
-
In the patent: "Numerous approaches have been suggested for treating hair loss. Two of the most commonly used and accepted compounds for preventing hair loss are minoxidil, the active ingredient in Rogaine® and the 5α-reductase inhibitor, finasteride, the active ingredient in Propecia®. However, cosmetic treatment of age-related hair loss in patients with topical solution of minoxidil or finasteride has resulted in only moderate regrowth of hair in less than 40% of such patients. Indeed, less than ten percent of the men who use Rogaine® achieve satisfactory results. Thus, there is a need in the art for more effective methods of, and compositions for treating hair loss. Preferably, new methods and compositions will require fewer applications of active ingredients; provide hair regrowth sooner, in more abundance, and thicker, than presently observed with minoxidil or finasteride treatment.
It has been found that hair follicle development and regeneration are regulated by the canonical Wnt/β-catenin signaling pathway [Investigative Dermatology (2008), 128(5), 1081-1087]. In the epidermis, hair follicle development is initiated when mesenchymal cells populate the skin. During this process, signals emanating from the dermis induce epithelium thickening, elongation of the epithelial cells, and the formation of placodes containing Wnt-responsive cells. In response, placodes signal dermal cells to condense, thereby forming the dermal papilla component of the hair follicle, which is also responsive to Wnt signaling. Wnt3α is secreted from hair epithelium and acts in an autocrine and paracrine fashion, and it has been demonstrated that Wnt-3α maintains anagen gene expression in dermal papilla cells and mediates hair-inductive activity in an organ culture. This Wnt-3α-mediated hair growth might depend on the canonical Wnt/β-catenin signaling pathway because deletion of β-catenin or the Lef1 gene resulted in hair loss in mice. Therefore, activation of β-catenin by Wnt contributes to the inhibition of keratinocytes differentiation, induction of hair follicle formation, and maintenance of proliferation of neuronal progenitors."
BTW, there are A LOT of peer reviewed journals that show WNT-3a maintains anagen expression, activates b-catenin, thus maintaining hair inducing properties.Comment
-
In the patent: "Numerous approaches have been suggested for treating hair loss. Two of the most commonly used and accepted compounds for preventing hair loss are minoxidil, the active ingredient in Rogaine® and the 5α-reductase inhibitor, finasteride, the active ingredient in Propecia®. However, cosmetic treatment of age-related hair loss in patients with topical solution of minoxidil or finasteride has resulted in only moderate regrowth of hair in less than 40% of such patients. Indeed, less than ten percent of the men who use Rogaine® achieve satisfactory results. Thus, there is a need in the art for more effective methods of, and compositions for treating hair loss. Preferably, new methods and compositions will require fewer applications of active ingredients; provide hair regrowth sooner, in more abundance, and thicker, than presently observed with minoxidil or finasteride treatment.
It has been found that hair follicle development and regeneration are regulated by the canonical Wnt/β-catenin signaling pathway [Investigative Dermatology (2008), 128(5), 1081-1087]. In the epidermis, hair follicle development is initiated when mesenchymal cells populate the skin. During this process, signals emanating from the dermis induce epithelium thickening, elongation of the epithelial cells, and the formation of placodes containing Wnt-responsive cells. In response, placodes signal dermal cells to condense, thereby forming the dermal papilla component of the hair follicle, which is also responsive to Wnt signaling. Wnt3α is secreted from hair epithelium and acts in an autocrine and paracrine fashion, and it has been demonstrated that Wnt-3α maintains anagen gene expression in dermal papilla cells and mediates hair-inductive activity in an organ culture. This Wnt-3α-mediated hair growth might depend on the canonical Wnt/β-catenin signaling pathway because deletion of β-catenin or the Lef1 gene resulted in hair loss in mice. Therefore, activation of β-catenin by Wnt contributes to the inhibition of keratinocytes differentiation, induction of hair follicle formation, and maintenance of proliferation of neuronal progenitors."
BTW, there are A LOT of peer reviewed journals that show WNT-3a maintains anagen expression, activates b-catenin, thus maintaining hair inducing properties.
Does this only work on the Wnt - Wnt3? I hoped it worked on all Wnts. Everyone knows Wnt7 is instrumental to hair growth.
Also, I appreciate your excerpt and it was great reading but I did not see where it said that this patent is for SM04554. Can you please tell me how you know for sure that this patent is for SM04554?Comment
-
Does this only work on the Wnt - Wnt3? I hoped it worked on all Wnts. Everyone knows Wnt7 is instrumental to hair growth.
Also, I appreciate your excerpt and it was great reading but I did not see where it said that this patent is for SM04554. Can you please tell me how you know for sure that this patent is for SM04554?
I sincerely hope you're not trying to get someone to make this stuff. If made improperly, this stuff could maybe cause cancer.Comment
-
I'm fairly certain this is the patent. It's the only Samumed patent that includes anything related to hair or WNT activation and hair. Also, it was filed a few months before their phase 1 trial.
I sincerely hope you're not trying to get someone to make this stuff. If made improperly, this stuff could maybe cause cancer.Comment
-
I'm fairly certain this is the patent. It's the only Samumed patent that includes anything related to hair or WNT activation and hair. Also, it was filed a few months before their phase 1 trial.
I sincerely hope you're not trying to get someone to make this stuff. If made improperly, this stuff could maybe cause cancer.
The blackmarket drug-makers, such as Kane, have chemists on board who go through patents with a fine tooth comb and fully understand these patents. They know what they're doing.Comment
-
I'm fairly certain this is the patent. It's the only Samumed patent that includes anything related to hair or WNT activation and hair. Also, it was filed a few months before their phase 1 trial.
I sincerely hope you're not trying to get someone to make this stuff. If made improperly, this stuff could maybe cause cancer.Comment
-
Some of us at the bald truth are talking about funding Hellouser's trip to the upcoming Hair Loss Congress the same way we funded Desmond's trip last year. Perhaps if we funded Hellouser's trip he could go in as a press-person the same as Desmond did last year, and if he went in as a press person he could maybe interview the staff involved with SM04554, and maybe during the interview he could find out from the company which of the 3 compounds is SM04554.Comment
Comment